| EU6 Stock | | | EUR 1.67 0.09 5.70% |
CEO
Frank BeduAddo is President, Chief Executive Officer, Director of PDS Biotechnology Corp since 2020.
| Age | 58 |
| Tenure | 5 years |
| Phone | 800 208 3343 |
| Web | https://www.pdsbiotech.com |
PDS Biotechnology Management Efficiency
The company has return on total asset
(ROA) of
(0.2487) % which means that it has lost $0.2487 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.488) %, meaning that it generated substantial loss on money invested by shareholders. PDS Biotechnology's management efficiency ratios could be used to measure how well PDS Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities.
PDS Biotechnology Corp has accumulated 552.98
K in total debt with debt to equity ratio
(D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. PDS Biotechnology Corp has a current ratio of 18.84, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist PDS Biotechnology until it has trouble settling it off, either with new capital or with free cash flow. So, PDS Biotechnology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PDS Biotechnology Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PDS to invest in growth at high rates of return. When we think about PDS Biotechnology's use of debt, we should always consider it together with cash and equity.
Similar Executives
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey. PDS BIOTECHNOLOGY operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15 people. PDS Biotechnology Corp (EU6) is traded on Frankfurt Exchange in Germany and employs 22 people.
Management Performance
PDS Biotechnology Corp Leadership Team
Elected by the shareholders, the PDS Biotechnology's board of directors comprises two types of representatives: PDS Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PDS. The board's role is to monitor PDS Biotechnology's management team and ensure that shareholders' interests are well served. PDS Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PDS Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Otis Brawley, Director | |
| Joe Dervan, VP RD | |
| Deanne Randolph, VP Relations | |
| Gregory Conn, Chief Scientific Officer | |
| Spencer JD, Sr Counsel | |
| Nathalie Riebel, VP Operations | |
| Janetta Trochimiuk, Controller | |
| Stephen Glover, Independent Chairman of the Board | |
| Lauren Wood, Chief Medical Officer | |
| Richard Sykes, Independent Director | |
| Gregory Freitag, Independent Director | |
| Seth Voorhees, Chief Financial Officer | |
| Sanjay Zaveri, Sr Devel | |
| DeLyle Bloomquist, Independent Director | |
| Kamil AliJackson, Independent Director | |
| Michael King, Interim Chief Financial Officer | |
| Frank BeduAddo, President, Chief Executive Officer, Director | |
| Lauren MD, Chief Officer | |
| Ilian Iliev, Director | |
| Matthew CPA, Principal CFO | |
PDS Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PDS Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in PDS Stock
When determining whether PDS Biotechnology Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of PDS Biotechnology's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Pds Biotechnology Corp Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Pds Biotechnology Corp Stock: Check out
Investing Opportunities to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
You can also try the
Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.